FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046229568> ?p ?o ?g. }

• W3046229568 abstract "This meta-analysis aimed to evaluate the risk of developing bullous pemphigoid (BP) and other skin-related adverse events (AEs) in patients with type 2 diabetes (T2DM) undergoing dipeptidyl peptidase-4 inhibitor (DPP-4i) treatment in randomized controlled trials (RCTs).In this meta-analysis, the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials databases were searched for RCTs, which involve patients with T2DM reporting skin-related AEs. RCTs that comparatively evaluated the effects of DPP-4i treatment and placebo on patients with T2DM and reported skin-related AEs were included in the analysis. The odds ratio (OR) and 95% confidence interval (CI) were calculated using the Peto's methods. The GRADE approach was used to rate the quality of evidence.A total of 46 randomized placebo-controlled trials, including 3 trials with reports of BP (n = 38 011), that reported skin-related AEs were included (n = 59 332). Compared to the placebo group, the risk of developing BP was significantly higher in the DPP-4i treatment group (OR = 7.38, 95% CI 2.00-27.25, I2 = 0%, P = .003; quality rating: very low). Additionally, DPP-4i treatment was associated with an increased overall risk of developing skin-related AEs (OR = 1.22, 95% CI 1.02-1.46, I2 = 32%, P = .03; quality rating: moderate).This meta-analysis suggested that treatment with DPP-4is, including sitagliptin, saxagliptin, and linagliptin, was associated with an increased risk of developing BP. Additionally, the risk of developing skin-related AEs increased when all DPP-4is were combined. Skin lesion, especially BP, should be monitored in patients with diabetes undergoing DPP-4i treatment. Future studies should evaluate the susceptible population and develop strategies for early detection of skin-related AEs." @default.
• W3046229568 created "2020-08-07" @default.
• W3046229568 creator A5000693667 @default.
• W3046229568 creator A5018058348 @default.
• W3046229568 creator A5049710746 @default.
• W3046229568 creator A5054525661 @default.
• W3046229568 date "2020-08-28" @default.
• W3046229568 modified "2023-09-27" @default.
• W3046229568 title "Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials" @default.
• W3046229568 cites W1512997554 @default.
• W3046229568 cites W1547857602 @default.
• W3046229568 cites W1554419393 @default.
• W3046229568 cites W1615542701 @default.
• W3046229568 cites W1896853883 @default.
• W3046229568 cites W1911149840 @default.
• W3046229568 cites W1951261947 @default.
• W3046229568 cites W1970125713 @default.
• W3046229568 cites W1971471384 @default.
• W3046229568 cites W1983130067 @default.
• W3046229568 cites W2003195877 @default.
• W3046229568 cites W2005368757 @default.
• W3046229568 cites W2006925617 @default.
• W3046229568 cites W2007872832 @default.
• W3046229568 cites W2015735533 @default.
• W3046229568 cites W2026669955 @default.
• W3046229568 cites W2027223556 @default.
• W3046229568 cites W2028927085 @default.
• W3046229568 cites W2038953694 @default.
• W3046229568 cites W2040643300 @default.
• W3046229568 cites W2042780785 @default.
• W3046229568 cites W2043326088 @default.
• W3046229568 cites W2045063167 @default.
• W3046229568 cites W2045321591 @default.
• W3046229568 cites W2056182647 @default.
• W3046229568 cites W2059245135 @default.
• W3046229568 cites W2059459105 @default.
• W3046229568 cites W2064130493 @default.
• W3046229568 cites W2064780710 @default.
• W3046229568 cites W2083473802 @default.
• W3046229568 cites W2083783651 @default.
• W3046229568 cites W2086842286 @default.
• W3046229568 cites W2092920113 @default.
• W3046229568 cites W2098923148 @default.
• W3046229568 cites W2103058881 @default.
• W3046229568 cites W2104053168 @default.
• W3046229568 cites W2104391911 @default.
• W3046229568 cites W2106154942 @default.
• W3046229568 cites W2126065052 @default.
• W3046229568 cites W2127854619 @default.
• W3046229568 cites W2134652590 @default.
• W3046229568 cites W2137270610 @default.
• W3046229568 cites W2140610722 @default.
• W3046229568 cites W2140986962 @default.
• W3046229568 cites W2142830692 @default.
• W3046229568 cites W2144193100 @default.
• W3046229568 cites W2145335273 @default.
• W3046229568 cites W2154277743 @default.
• W3046229568 cites W2155692205 @default.
• W3046229568 cites W2165010366 @default.
• W3046229568 cites W2171512247 @default.
• W3046229568 cites W2188407105 @default.
• W3046229568 cites W2288299997 @default.
• W3046229568 cites W2333003991 @default.
• W3046229568 cites W2395548559 @default.
• W3046229568 cites W2507467604 @default.
• W3046229568 cites W2528577049 @default.
• W3046229568 cites W2532067257 @default.
• W3046229568 cites W2586020475 @default.
• W3046229568 cites W2616456969 @default.
• W3046229568 cites W2769816356 @default.
• W3046229568 cites W2793163074 @default.
• W3046229568 cites W2804051772 @default.
• W3046229568 cites W2819950008 @default.
• W3046229568 cites W2887766728 @default.
• W3046229568 cites W2900149048 @default.
• W3046229568 cites W3014827204 @default.
• W3046229568 doi "https://doi.org/10.1002/dmrr.3391" @default.
• W3046229568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32741073" @default.
• W3046229568 hasPublicationYear "2020" @default.
• W3046229568 type Work @default.
• W3046229568 sameAs 3046229568 @default.
• W3046229568 citedByCount "11" @default.
• W3046229568 countsByYear W30462295682021 @default.
• W3046229568 countsByYear W30462295682022 @default.
• W3046229568 countsByYear W30462295682023 @default.
• W3046229568 crossrefType "journal-article" @default.
• W3046229568 hasAuthorship W3046229568A5000693667 @default.
• W3046229568 hasAuthorship W3046229568A5018058348 @default.
• W3046229568 hasAuthorship W3046229568A5049710746 @default.
• W3046229568 hasAuthorship W3046229568A5054525661 @default.
• W3046229568 hasConcept C126322002 @default.
• W3046229568 hasConcept C134018914 @default.
• W3046229568 hasConcept C142724271 @default.
• W3046229568 hasConcept C156490143 @default.
• W3046229568 hasConcept C156957248 @default.
• W3046229568 hasConcept C168563851 @default.
• W3046229568 hasConcept C197934379 @default.
• W3046229568 hasConcept C204787440 @default.
• W3046229568 hasConcept C27081682 @default.
• W3046229568 hasConcept C2777180221 @default.

• next